v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Summary of net loss reconciliation

The following table shows the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, for the three and six months ended June 30, 2026 and 2025 (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Denifanstat external research and
   development expenses

 

$

6,338

 

 

$

4,758

 

 

$

9,465

 

 

$

18,094

 

TVB-3567 external research and
   development expenses

 

 

2,056

 

 

 

1,386

 

 

 

4,429

 

 

 

2,220

 

External general and administrative
   expenses

 

 

1,555

 

 

 

2,379

 

 

 

3,682

 

 

 

4,631

 

Personnel costs

 

 

2,092

 

 

 

1,775

 

 

 

4,262

 

 

 

3,726

 

Stock-based compensation

 

 

3,691

 

 

 

1,598

 

 

 

5,530

 

 

 

3,070

 

Other segment items (1)

 

 

(1,779

)

 

 

(1,510

)

 

 

(2,765

)

 

 

(3,179

)

Segment net loss

 

$

13,953

 

 

$

10,386

 

 

$

24,603

 

 

$

28,562

 

 

(1)
Other segment items consist of (i) interest and other income, net and (ii) other internal operating research and development expenses.